Conferences

ecancer travels so that you don't have to. Expore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

ESMO 2012

28 Sep - 2 Oct 2012
Advice to young oncologists
Prof Jose Baselga - Memorial Sloan Kettering Cancer Center, New York, USA
Advice to young oncologists ( Prof Jose Baselga - Memorial Sloan Kettering Cancer Center, New York, USA )
15 Feb 2013
Evolving patient management in metastatic and non-metastatic castration-resistan...
Professor Noel Clarke, Dr Heather Payne, Prof Karim Fizazi,Prof John Fitzpatrick...
Evolving patient management in metastatic and non-metastatic castration-resistant prostate cancer ( Professor Noel Clarke, Dr Heather Payne, Prof Karim Fizazi,Prof John Fitzpatrick, Prof Bertrand Tombal )
12 Nov 2012
Advances in advanced renal cell carcinoma from ESMO 2012: Part 1
Prof Tim Eisen - Addenbrooke's Oncology Centre, UK, Prof Bernard Escudier - Inst...
Advances in advanced renal cell carcinoma from ESMO 2012: Part 1 ( Prof Tim Eisen - Addenbrooke's Oncology Centre, UK, Prof Bernard Escudier - Institut Gustave Roussy, France, Dr Thomas Powles - St Bartholomew Hospital, UK, Dr Thomas Hutson - Baylor Sammons Cancer Center, USA )
15 Oct 2012
Advances in advanced renal cell carcinoma from ESMO 2012: Part 3
Prof Tim Eisen - Addenbrooke's Oncology Centre, Cambridge, Prof Bernard Escudier...
Advances in advanced renal cell carcinoma from ESMO 2012: Part 3 ( Prof Tim Eisen - Addenbrooke's Oncology Centre, Cambridge, Prof Bernard Escudier - Institut Gustave Roussy, France, Dr Thomas Powles - St Bartholomew Hospital, London, Dr Thomas Hutson - Baylor Sammons Cancer Center, USA )
13 Oct 2012
Advances in advanced renal cell carcinoma from ESMO 2012: Part 2
Prof Tim Eisen - Addenbrooke's Oncology Centre, Cambridge, Prof Bernard Escudier...
Advances in advanced renal cell carcinoma from ESMO 2012: Part 2 ( Prof Tim Eisen - Addenbrooke's Oncology Centre, Cambridge, Prof Bernard Escudier - Institut Gustave Roussy, France, Dr Thomas Powles - St Bartholomew Hospital, London, Dr Thomas Hutson - Baylor Sammons Cancer Center, USA )
13 Oct 2012
Advances in advanced metastatic renal cell carcinoma from ESMO 2012
Dr Robert Motzer - The Memorial Sloan-Kettering Cancer Center, USA
Advances in advanced metastatic renal cell carcinoma from ESMO 2012 ( Dr Robert Motzer - The Memorial Sloan-Kettering Cancer Center, USA )
12 Oct 2012
Treating platinum resistant ovarian cancer
Dr Andres Poveda – Fundacion Instituto Valenciano de Oncologia, Spain
Treating platinum resistant ovarian cancer ( Dr Andres Poveda – Fundacion Instituto Valenciano de Oncologia, Spain )
12 Oct 2012
Developing technologies for personalised treatment
Dr Atanasio Pandiella – Instituto de Biologia Molecular y Celular del Cancer, Sa...
Developing technologies for personalised treatment ( Dr Atanasio Pandiella – Instituto de Biologia Molecular y Celular del Cancer, Salamanca, Spain )
12 Oct 2012
Nab-paclitaxel and gemcitabine combating pancreatic cancer
Dr Michel Ducreux – Institut Gustave Roussy, Paris, France
Nab-paclitaxel and gemcitabine combating pancreatic cancer ( Dr Michel Ducreux – Institut Gustave Roussy, Paris, France )
12 Oct 2012
Chemotherapy and radiotherapy in advanced local non-small cell lung cancer
Dr Dirk De Ruysscher – University of Leuven, Netherlands
Chemotherapy and radiotherapy in advanced local non-small cell lung cancer ( Dr Dirk De Ruysscher – University of Leuven, Netherlands )
12 Oct 2012
Hepatic chemosaturation therapy
Dr Krishna Kandarpa – Delcath Systems Inc, Dr Pier Ferrucci – European Insitute ...
Hepatic chemosaturation therapy ( Dr Krishna Kandarpa – Delcath Systems Inc, Dr Pier Ferrucci – European Insitute of Oncology, Milan, Italy )
11 Oct 2012
Advances in soft tissue sarcoma from ESMO 2012
Prof Jean Yves Blay - Université Claude Bernard, France
Advances in soft tissue sarcoma from ESMO 2012 ( Prof Jean Yves Blay - Université Claude Bernard, France )
11 Oct 2012
Genes, chromosomes and the treatment of bladder cancer
Dr Jonathan Rosenburg - Memorial Sloan Kettering Cancer Center, New York, USA
Genes, chromosomes and the treatment of bladder cancer ( Dr Jonathan Rosenburg - Memorial Sloan Kettering Cancer Center, New York, USA )
10 Oct 2012
Analysing the efficacy of treatment through Response Evaluation Criteria in Soli...
Dr Yves Menu – Saint Antoine Hospital, Paris, France
Analysing the efficacy of treatment through Response Evaluation Criteria in Solid Tumors (RECIST) ( Dr Yves Menu – Saint Antoine Hospital, Paris, France )
9 Oct 2012
Surgical challenges to retroperitoneal sarcomas
Dr Angelo Dei Tos – Department of Oncology, General Hospital of Treviso, Italy
Surgical challenges to retroperitoneal sarcomas ( Dr Angelo Dei Tos – Department of Oncology, General Hospital of Treviso, Italy )
9 Oct 2012
Treatment approaches for desmoid tumours
Dr Sylvie Bonvalot – Institut Gustave Roussy, Paris, France
Treatment approaches for desmoid tumours ( Dr Sylvie Bonvalot – Institut Gustave Roussy, Paris, France )
9 Oct 2012
Development and expansion of the IFOM-IEO campus
Prof Marco Foiani – University of Milan, Italy and Scientific Director IFOM
Development and expansion of the IFOM-IEO campus ( Prof Marco Foiani – University of Milan, Italy and Scientific Director IFOM )
9 Oct 2012
Standard of care for neo-adjuvant therapy in HER 2 and triple negative subtype
Dr Fatima Cardoso – Champalimaud Cancer Center, Lisbon, Portugal
Standard of care for neo-adjuvant therapy in HER 2  and triple negative subtype ( Dr Fatima Cardoso – Champalimaud Cancer Center, Lisbon, Portugal )
9 Oct 2012
Clinical trials and drug developments in pancreatic cancer
Dr Roberto Labianca – Ospedali Riuniti Bergamo, Italy
Clinical trials and drug developments in pancreatic cancer ( Dr Roberto Labianca – Ospedali Riuniti Bergamo, Italy )
9 Oct 2012
The Neo ALTO Study, combination therapy of lapatinib and trastuzumab and breast ...
Dr Carmen Criscitiello - European Institute of Oncology, Milan, Italy
The Neo ALTO Study, combination therapy of lapatinib and trastuzumab and breast conservation surgery ( Dr Carmen Criscitiello - European Institute of Oncology, Milan, Italy )
9 Oct 2012
Advances in advanced prostate cancer from ESMO 2012; focus on abiraterone acetat...
Dr Chris Parker , Dr Charles Ryan, Prof Karim Fizazi
Advances in advanced prostate cancer from ESMO 2012; focus on abiraterone acetate ( Dr Chris Parker , Dr Charles Ryan, Prof Karim Fizazi )
9 Oct 2012
Histology and non-histology driven therapy for soft tissue sarcomas and the Rare...
Dr Paolo Casali – Instituto Nazionale Tumori, Milan, Italy
Histology and non-histology driven therapy for soft tissue sarcomas and the Rare Cancers Europe initiative ( Dr Paolo Casali – Instituto Nazionale Tumori, Milan, Italy )
9 Oct 2012
MET inhibitors for non-small cell lung cancer
Prof Georgio Scagliotti – University of Torino, Italy
MET inhibitors for non-small cell lung cancer ( Prof Georgio Scagliotti – University of Torino, Italy )
9 Oct 2012
Multidisciplinary benefits to radiotherapy
Prof Vincenzo Valentini – President of ESTRO
Multidisciplinary benefits to radiotherapy ( Prof Vincenzo Valentini – President of ESTRO )
9 Oct 2012
Pathology and development of ovarian cancer
Dr Jamie Prat – Hospital De La Santa Creu I San Pau, Spain
Pathology and development of ovarian cancer ( Dr Jamie Prat – Hospital De La Santa Creu I San Pau, Spain )
9 Oct 2012
Putting the theory of personalised medicine into practice
Prof Fabrice Andre, Dr Ramesh Ramanathan, Prof Peter Harper and Prof Robert Leon...
Putting the theory of personalised medicine into practice ( Prof Fabrice Andre, Dr Ramesh Ramanathan, Prof Peter Harper and Prof Robert Leonard )
8 Oct 2012
Treatment of ALK+ lung cancer with crizotinib, Profile 1007
Dr Alice Shaw – Massachusetts General Hospital, Boston, USA
Treatment of ALK+ lung cancer with crizotinib, Profile 1007 ( Dr Alice Shaw – Massachusetts General Hospital, Boston, USA )
8 Oct 2012
The first phase II trial for the management of oesophageal cancer
Prof David Ferry – New Cross Hospital, Wolverhampton, UK
The first phase II trial for the management of oesophageal cancer  ( Prof David Ferry – New Cross Hospital, Wolverhampton, UK )
8 Oct 2012
Phase III MISSION trial: Sorafenib does not extend overall survival as third or ...
Dr Tony Mok – The Chinese University of Hong Kong
Phase III MISSION trial: Sorafenib does not extend overall survival as third or fourth line therapy in lung cancer ( Dr Tony Mok – The Chinese University of Hong Kong )
8 Oct 2012
Trametinib and dabrafenib combination therapy against metastatic melanoma
Dr Georgina Long – Westmead Hospital, The University of Sydney, Australia
Trametinib and dabrafenib combination therapy against metastatic melanoma ( Dr Georgina Long – Westmead Hospital, The University of Sydney, Australia )
8 Oct 2012
New developments in molecular imaging
Prof Wim Oyen – Radboud University Nijmagen Medical Centre, Netherlands
New developments in molecular imaging ( Prof Wim Oyen – Radboud University Nijmagen Medical Centre, Netherlands )
5 Oct 2012
Personalised cancer medicine and research: Today’s best practice
Prof José Baselga - Massachusetts General Hospital, Boston, USA
Personalised cancer medicine and research: Today’s best practice ( Prof José Baselga - Massachusetts General Hospital, Boston, USA )
5 Oct 2012
Treating liver metastases in colorectal cancer
Dr Gunnar Folprecht - University Cancer Center, Dresden, Germany
Treating liver metastases in colorectal cancer ( Dr Gunnar Folprecht - University Cancer Center, Dresden, Germany )
4 Oct 2012
Putting drugs to work against brain metastases in HER2 positive breast cancer: L...
Dr Thomas Bachelot – Centre Leon Berard, Lyon
Putting drugs to work against brain metastases in HER2 positive breast cancer: LANDSCAPE study ( Dr Thomas Bachelot – Centre Leon Berard, Lyon )
4 Oct 2012
The Multinational Association of Supportive Care in Cancer (MASCC)
Dr Stephen Grunberg – University of Vermont, Burlington, USA
The Multinational Association of Supportive Care in Cancer (MASCC) ( Dr Stephen Grunberg – University of Vermont, Burlington, USA )
4 Oct 2012
Defining personalised medicine and patient empowerment
Prof Gabriella Pravettoni – University of Milan, Italy
Defining personalised medicine and patient empowerment ( Prof Gabriella Pravettoni – University of Milan, Italy )
4 Oct 2012
Phase I study examining PI 3 kinase inhibitor for various tumours
Dr Pamela Munster – University of California, San Francisco, USA
Phase I study examining PI 3 kinase inhibitor for various tumours ( Dr Pamela Munster – University of California, San Francisco, USA )
4 Oct 2012
Phase III trial shows crizotinib superior to single-agent chemotherapy for ALK-p...
Dr Alice Shaw - Massachusetts General Hospital Cancer Center, Boston, USA
Phase III trial shows crizotinib superior to single-agent chemotherapy for ALK-positive lung cancer ( Dr Alice Shaw - Massachusetts General Hospital Cancer Center, Boston, USA )
30 Sep 2012
A proof-of-concept study of ODM-201 in patients with progressive castration-resi...
Dr Christophe Massard - Institute Gustave Roussy, Paris, France
A proof-of-concept study of ODM-201 in patients with progressive castration-resistant prostate cancer ( Dr Christophe Massard - Institute Gustave Roussy, Paris, France )
30 Sep 2012
Too few women being offered breast-conserving treatment?
Dr Carmen Criscitiello - European Institute of Oncology in Milan, Italy
Too few women being offered breast-conserving treatment? ( Dr Carmen Criscitiello - European Institute of Oncology in Milan, Italy )
30 Sep 2012
Personalised medicine: Hype or hope?
Jola Gore Booth - Europacolon
Personalised medicine: Hype or hope? ( Jola Gore Booth - Europacolon )
30 Sep 2012
Awareness of personalised medicine in cancer patients
Dr Sabine Tejpar - University Hospital Gasthuisberg, Lueven, Belgium
Awareness of personalised medicine in cancer patients ( Dr Sabine Tejpar - University Hospital Gasthuisberg, Lueven, Belgium )
30 Sep 2012
BRAF inhibitor dabrafenib alone vs combination with MEK1/2 inhibitor trametinib ...
Dr Georgina Long - Melanoma Institute Australia, Sydney, Australia
BRAF inhibitor dabrafenib alone vs combination with MEK1/2 inhibitor trametinib for melanoma ( Dr Georgina Long - Melanoma Institute Australia, Sydney, Australia )
29 Sep 2012
Phase I and II trials focus on drug combination slowing development of resistanc...
Prof Yossef Yarden - Weizmann Institute of Science, Israel.
Phase I and II trials focus on drug combination slowing development of resistance inhibiting BRAF ( Prof Yossef Yarden - Weizmann Institute of Science, Israel. )
29 Sep 2012
Gefitinib versus placebo in oesophageal cancer progressing after chemotherapy
Prof David Ferry - New Cross Hospital, Wolverhampton, UK
Gefitinib versus placebo in oesophageal cancer progressing after chemotherapy ( Prof David Ferry - New Cross Hospital, Wolverhampton, UK )
29 Sep 2012
Biomarker analysis of MISSION: EGFR lung tumours may benefit from sorafenib
Dr Tony Mok - Chinese University of Hong Kong
Biomarker analysis of MISSION: EGFR lung tumours may benefit from sorafenib ( Dr Tony Mok - Chinese University of Hong Kong )
29 Sep 2012
Sorafenib does not extend overall survival as third or fourth line therapy in lu...
Dr Luis Paz-Ares - Virgen del Rocio University Hospital in Seville, Spain
Sorafenib does not extend overall survival as third or fourth line therapy in lung cancer – Phase III MISSION trial ( Dr Luis Paz-Ares - Virgen del Rocio University Hospital in Seville, Spain )
29 Sep 2012